PCOS Immune Function Predicts Metformin Efficacy
Prediction of Immune Status on the Efficacy of Metformin in the Treatment of Polycystic Ovary Syndrome
Shanghai 10th People's Hospital
100 participants
Mar 16, 2024
INTERVENTIONAL
Conditions
Summary
In this study, the investigators will include PCOS patients who meet the trial criteria, introduce participants to the content of this study, and invite participants to participate. The immune function of peripheral blood samples of PCOS patients was detected by flow cytometry. Participants were further treated with metformin for 6 months and followed up after the intervention. The objective of this study was to investigate immune markers related to the efficacy of metformin in PCOS patients and to predict the efficacy of metformin in PCOS patients using immune function.
Eligibility
Inclusion Criteria2
- aged 18-45 years
- Diagnosis of PCOS with the Rotterdam diagnosis criteria (2003)
Exclusion Criteria10
- Pregnant women;
- Hyperthyroidism or hypothyroidism
- Severe liver and kidney function injury
- Cancer patients;
- Associated with severe infection, severe anemia, neutropenia and other blood system diseases;
- Have type 1 diabetes, single-gene mutated diabetes or other secondary diabetes;
- Patients with mental illness or intellectual disability;
- Have taken drugs for PCOS treatment in the last three months;
- Have a long history of taking hormone therapy;
- Currently or recently participating in another clinical trial.
Interventions
Take metformin for six months.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06325956